KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2016 - 2017)

Supernus Pharmaceuticals (SUPN) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $1.1 million as the latest value for Q4 2017.

  • Quarterly Non-Current Deffered Revenue fell 23.45% to $1.1 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2017, down 23.45% year-over-year, with the annual reading at $1.1 million for FY2017, 23.45% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2017 was $1.1 million at Supernus Pharmaceuticals, down from $1.2 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $1.7 million in Q1 2016, with the low at $738000.0 in Q2 2013.
  • Average Non-Current Deffered Revenue over 5 years is $1.3 million, with a median of $1.3 million recorded in 2014.
  • The sharpest move saw Non-Current Deffered Revenue surged 358.58% in 2013, then decreased 23.45% in 2017.
  • Over 5 years, Non-Current Deffered Revenue stood at $1.4 million in 2013, then decreased by 10.09% to $1.3 million in 2014, then rose by 9.11% to $1.4 million in 2015, then rose by 7.99% to $1.5 million in 2016, then fell by 23.45% to $1.1 million in 2017.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1.1 million, $1.2 million, and $1.3 million for Q4 2017, Q3 2017, and Q2 2017 respectively.